Reata Pharmaceuticals registers $80 million for IPO of common stock

Citigroup, Cowen, Piper Jaffray fund development, preclinical programs

By Devika Patel

Knoxville, Tenn., Jan. 4 – Reata Pharmaceuticals, Inc. will price its initial public sale of class A common stock with a 30-day greenshoe, according to a Form S-1 filed Monday with the Securities and Exchange Commission. The company has registered up to $80 million of stock.

Citigroup, Cowen and Co. and Piper Jaffray are the bookrunners.

Proceeds will be used for development of bardoxolone methyl, development of RTA 408, preclinical programs, working capital and other general corporate purposes.

The biopharmaceutical company is based in Irving, Texas. The company intends to list its stock on the Nasdaq stock exchange under the symbol “RETA.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.